A MOTS-C Hydrogel for Mitochondrial Transplantation After Heart Attack

Mitochondrial transplantation — taking healthy mitochondria and delivering them directly into damaged tissue — has been a research interest in cardiology for over a decade, on the theory that a heart attack’s damage is driven as much by mitochondrial failure in surviving tissue as by the initial loss of blood flow. The idea has struggled to move past preclinical work for a mundane reason: isolated mitochondria are fragile and lose functional viability within hours of being taken out of a cell. A study published in Bioactive Materials in August 2026 tackles that fragility problem using MOTS-C, the mitochondrial-derived peptide already familiar to peptide researchers from metabolic and exercise-signaling work, repurposed here as a structural and functional component of a delivery hydrogel.

The core problem: donor mitochondria don’t survive the trip

In a myocardial infarction (heart attack), affected heart tissue experiences oxidative stress, excessive inflammation, and mitochondrial dysfunction in the surviving cardiomyocytes. Transplanting fresh, functional mitochondria into that environment is a logical intervention, but the practical bottleneck has been keeping the donor mitochondria alive and functional long enough to have an effect once delivered. Isolated mitochondria are exposed to oxidative stress and calcium overload almost immediately, and most preclinical mitochondrial-transplantation work has had to work around a narrow viability window.

Building a MOTS-C-based delivery vehicle

The research team’s approach was to conjugate MOTS-C to a self-assembling peptide (Q11) to form a hydrogel scaffold, which they designate MQgel, and then load it with isolated mitochondria to create the full delivery system (MQgel@Mito). In their testing, the hydrogel extended the survival of isolated mitochondria and preserved metabolic enzyme activity for at least eight hours — a meaningful improvement over unprotected isolated mitochondria. The hydrogel also appeared to shield the donor mitochondria from oxidative stress and calcium overload during that window.

The choice of MOTS-C for this role isn’t incidental. The peptide’s proposed mechanism centers on AMPK pathway activation, and the researchers report that MQgel enhanced mitochondrial uptake by macrophages through an AMPK-dependent process — consistent with the broader research literature on MOTS-C’s role in cellular energy signaling, here applied to a new, more structural application rather than a purely metabolic one.

What happened in the rat model

In a rat myocardial infarction model, MQgel@Mito reduced infiltration of pro-inflammatory (M1) macrophages and reduced cardiomyocyte damage, which the authors linked to improved cardiac function and less pathological remodeling of the heart tissue afterward. Mechanistically, the study reports that the delivered mitochondria pushed macrophage metabolism away from pro-inflammatory glycolysis and toward oxidative phosphorylation — a metabolic reprogramming that dampened M1 polarization, reduced reactive oxygen species, and appeared to protect macrophages themselves from apoptosis.

The authors frame this as evidence that macrophage immunometabolism — how immune cells fuel themselves, not just what signals they release — is a viable target for post-infarction cardiac therapy, with the MOTS-C hydrogel functioning as the delivery mechanism that makes mitochondrial transplantation practical enough to test that idea.

What this means for MOTS-C research

For researchers tracking MOTS-C specifically, this study is notable less for what it says about the peptide’s own bioactivity and more for how it’s being used: as a functional scaffold component rather than a standalone signaling molecule. It extends MOTS-C’s established AMPK-pathway mechanism into cardiac immunometabolism and tissue-engineering territory, alongside the more familiar metabolic and exercise-signaling research areas the peptide is usually associated with.

This remains rodent-model, preclinical work — a hydrogel-based delivery system tested in a single animal model of myocardial infarction, not a human clinical study, and not a therapy available outside a research setting. It adds a data point to the broader mitochondrial-derived peptide literature rather than establishing a treatment.

Further reading

Li H, et al. “Mitochondria-derived peptide hydrogel augments mitochondrial transplantation for promoting cardiac repair via macrophage metabolic reprogramming.” Bioactive Materials, 2026 Aug 14;67:458-476. PMID: 42633281 · DOI: 10.1016/j.bioactmat.2026.06.010